Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This prompts us to pursue 3q26 (or PIK3CA) prognostic evaluation in a larger population of head and neck squamous cell carcinomas.
|
11358835 |
2001 |
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas.
|
11959846 |
2002 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas.
|
11959846 |
2002 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Activity of the downstream PI3K effector protein kinase B (PKB) was higher in SqCas than in AdCas and was correlated with PIK3CA copy number (r = 0.75), suggesting that these copy number increases contribute to activation of PI3K signaling in SqCas of the lung.
|
12097266 |
2002 |
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Genomic gain of PIK3CA and increased expression of p110alpha are associated with progression of dysplasia into invasive squamous cell carcinoma.
|
12375266 |
2002 |
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Two novel oncogenes, namely squamous cell carcinoma (SCC)-related oncogene (SCCRO) and PIK3CA (gene encoding phosphatidylinositol-3 kinase catalytic alpha-polypeptide), have been identified as targets of 3q26.3 amplification.
|
12796399 |
2003 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The PIK3CA was amplified in 70% of squamous carcinomas, 38% of large cell carcinomas, 19% of adenocarcinomas, and 67% of small cell lung cancers.
|
15317667 |
2004 |
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
No somatic changes were detected in PIK3CB This study extends previous observations in other tumor types by demonstrating the presence of somatic PIK3CA mutations in both SCC and adenocarcinoma of the esophagus, thus implicating the PI3K pathway in the initiation and/or progression of esophageal cancers.
|
16380997 |
2006 |
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
PIK3CA mutations in head and neck squamous cell carcinoma.
|
16533766 |
2006 |
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
PIK3CA and TFRC located in 3q are new prognostic factors in esophageal squamous cell carcinoma.
|
16788758 |
2006 |
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
PIK3CA mutation incidence was significantly lower in adenocarcinoma (2/135, 1.5%) than in squamous cell carcinoma (5/77, 6.5%, p=0.0495).
|
16930767 |
2006 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
An increase in the copy number of PIK3CA, although small, was detected in 57.1% (8/14) of OSCC lines and 16.7% (18/108) of OSCC tumors using quantitative real-time PCR.
|
17052259 |
2006 |
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
An increase in the copy number of PIK3CA, although small, was detected in 57.1% (8/14) of OSCC lines and 16.7% (18/108) of OSCC tumors using quantitative real-time PCR.
|
17052259 |
2006 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
LHGDN |
Analysis of PIK3CA and Akt/protein kinase B in head and neck squamous cell carcinoma.
|
17549376 |
2007 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
PIK3CA amplification incidence was significantly higher in male, smoker and squamous cell carcinoma patients.
|
17681398 |
2007 |
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas.
|
18097548 |
2008 |
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
After SCC transformation, the absence of G45 domain in DeltaG45 cells was associated with deficient extracellular signal-regulated kinase and phosphotidylinositol 3-kinase (PI3K) pathway activation, impaired invasion, deficient metalloproteinase activity, and absent tumorgenicity in vivo.
|
18413757 |
2008 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
PIK3CA copy number gains were more frequent in squamous cell carcinoma (33.1%) than in adenocarcinoma (6.2%) or SCLC lines (4.7%).
|
18757405 |
2008 |
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The majority of OSCC cell lines showed an activation of PI3K/Akt signaling, and enforced expression of NDRG2 in HSC-3 cells decreased the level of phosphorylated Akt at Serine 473 (p-Akt).
|
20045673 |
2010 |
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We therefore screened 61 non-melanoma skin cancer samples (30 SCC and 31 BCC) for the presence of activating PIK3CA and AKT1 mutations.
|
20557351 |
2010 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy.
|
21110697 |
2011 |
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In tumor types with more than 10 patients tested, PIK3CA mutations were most frequent in endometrial (3 of 14, 21%), ovarian (5 of 30, 17%), colorectal (9 of 54, 17%), breast (2 of 14, 14%), cervical (2 of 15, 13%), and squamous cell cancer of the head and neck (1 of 11, 9%).
|
21216929 |
2011 |
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The knowledge of the PIK3CA's involvement in OSCC is important because a specific kinase inhibitor could be considered as a future therapeutic option for OSCC patients with PIK3CA mutations.
|
21824802 |
2011 |
Squamous cell carcinoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Knockdown of PLC-γ1 or PIKE blocked EGF-induced activation of class Ia PI3K and protein kinase C-ζ and phosphorylation of nucleolin in the nucleus as well as EGF-induced SCC cell proliferation.
|
22349826 |
2012 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In silico screening of candidate therapeutic compounds using subtype-specific pathway components identified HDAC and PI3K inhibitors as potential treatments tailored to lung SqCC.
|
22629454 |
2012 |